Combating the Progression of Novel Coronavirus SARS-CoV-2 Infectious Disease: Current State and Future Prospects in Molecular Diagnostics and Drug Discovery
Tóm tắt
Từ khóa
Tài liệu tham khảo
Chen N.; Zhou M.; Dong X.; Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020,395(10223),507-513
Tian J.; Yuan X.; Xiao J.; Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: A multicentre, retrospective, cohort study. Lancet Oncol 2020,21(7),893-903
Huang C.; Wang Y.; Li X.; Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020,395(10223),497-506
Naming the coronavirus disease (COVID-19) and the virus that causes it. 2020.Accessed online on 8th of. World Heal Organ WHOAvailable from: 2020,1
Su S.; Wong G.; Shi W.; Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016,24(6),490-502
Bruenn J.A.; A structural and primary sequence comparison of the viral RNA-dependent RNA polymerases. Nucleic Acids Res 2003,31(7),1821-1829
Zhou Y.; Jiang S.; Du L.; Prospects for a MERS-CoV spike vaccine. Expert Rev Vaccines 2018,17(8),677-686
Du L.; Tai W.; Zhou Y.; Jiang S.; Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines 2016,15(9),1123-1134
Chan J.F.W.; To K.K.W.; Tse H.; Jin D.Y.; Yuen K.Y.; Interspecies transmission and emergence of novel viruses: Lessons from bats and birds. Trends Microbiol 2013,21(10),544-555
Chan J.F.W.; Kok K.H.; Zhu Z.; Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020,9(1),221-236
Guo Y.R.; Cao Q.D.; Hong Z.S.; Tan Y.Y.; Chen S.D.; Jin H.J.; The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- An update on the status. Mil Med Res 2020,7,1-10
Zhu N.; Zhang D.; Wang W.; A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020,382(8),727-733
Chan J.F.W.; Yuan S.; Kok K.H.; A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 2020,395(10223),514-523
Zhou P.; Yang X.L.; Wang X.G.; A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020,579(7798),270-273
Li X.; Zai J.; Wang X.; Li Y.; Potential of large “first generation” human-to-human transmission of 2019-nCoV. J Med Virol 2020,92(4),448-454
Siordia J.A.; Epidemiology and clinical features of COVID-19: A review of current literature. J Clin Virol 2020,127,104357
Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) W.H. OrganizationAvailable from: 2019,1-6
Roncon L.; Zuin M.; Rigatelli G.; Zuliani G.; Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol 2020,127,104354
Hu Y.; Sun J.; Dai Z.; Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virol 2020,127,104371
Shiqin Li.; Li Sijia; Disoma C.; SARS‐CoV‐2: Mechanism of infection and emerging technologies for future prospects. Rev Med Virol 2020,e2168
Lai C.C.; Shih T.P.; Ko W.C.; Tang H.J.; Hsueh P.R.; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020,55(3),105924
Gao Z.; Xu Y.; Sun C.; Wang X.; Guo Y.; Qiu S.; A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect 2020,54(1),12-16
Ki M.; Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. Epidemiol Health 2020,42,e2020007
Kimball A.; Hatfield K.M.; Arons M.; James A.; Taylor J.; Spicer K.; Asymptomatic and presymptomatic SARS-COV-2 infections in residents of a long-term care skilled nursing facility - King County, Washington, March 2020. Morb Mortal Weekly Rep 2020,69,377-381
Yan Y.; Chang L.; Wang L.; Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. Rev Med Virol 2020,30(3),e2106
Boulware D.R.; Pullen M.F.; Bangdiwala A.S.; A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med 2020,383(6),517-525
Narota A.; Puri G.; Singh V.P.; Kumar A.; Naura A.S.; COVID-19 and ARDS: Update on preventive and therapeutic venues. Curr Mol Med 2021,21,1
Poon L.L.M.; Chan K.H.; Wong O.K.; Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol 2003,28(3),233-238
Poon L.L.M.; Wong O.K.; Chan K.H.; Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome (SARS). Clin Chem 2003,49(6 Pt 1),953-955
Lanciotti R.S.; Kerst A.J.; Nucleic acid sequence-based amplification assays for rapid detection of West Nile and St. Louis encephalitis viruses. J Clin Microbiol 2001,39(12),4506-4513
Mackay I.M.; Arden K.E.; Nitsche A.; Real-time PCR in virology. Nucleic Acids Res 2002,30(6),1292-1305
Smith I.L.; Halpin K.; Warrilow D.; Smith G.A.; Development of a fluorogenic RT-PCR assay (TaqMan) for the detection of Hendra virus. J Virol Methods 2001,98(1),33-40
Trujillo A.A.; McCaustland K.A.; Zheng D.P.; Use of TaqMan real-time reverse transcription-PCR for rapid detection, quantification, and typing of norovirus. J Clin Microbiol 2006,44(4),1405-1412
Drosten C.; Günther S.; Preiser W.; Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003,348(20),1967-1976
Corman V.M.; Landt O.; Kaiser M.; Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020,25(3),2000045
Lu R.; Zhao X.; Li J.; Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020,395(10224),565-574
Cui J.; Li F.; Shi Z.L.; Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019,17(3),181-192
Chu D.K.W.; Pan Y.; Cheng S.M.S.; Molecular diagnosis of a novel coronavirus (2019-ncov) causing an outbreak of pneumonia. Clin Chem 2020,66(4),549-555
Rothe C.; Schunk M.; Sothmann P.; Transmission of 2019-NCOV infection from an asymptomatic contact in Germany. N Engl J Med 2020,382(10),970-971
Holshue M.L.; DeBolt C.; Lindquist S.; First case of 2019 novel coronavirus in the United States. N Engl J Med 2020,382(10),929-936
Yang L.; Sinha T.; Carlson T.K.; Keiser T.L.; Torrelles J.B.; Schlesinger L.S.; Changes in the major cell envelope components of Mycobacterium tuberculosis during in vivo growth. Glycobiology 2013,23(8),926-934
Perchetti G.A.; Nalla A.K.; Huang M.L.; Jerome K.R.; Greninger A.L.; Multiplexing primer/probe sets for detection of SARS-CoV-2 by qRT-PCR. J Clin Virol 2020,129,104499
Nieto-Torres J.L.; Dediego M.L.; Álvarez E.; Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein. Virology 2011,415(2),69-82
Chang C.K.; Hou M.H.; Chang C.F.; Hsiao C.D.; Huang T.H.; The SARS coronavirus nucleocapsid protein-forms and functions. Antiviral Res 2014,103,39-50
Surjit M.; Lal S.K.; The SARS-CoV nucleocapsid protein: A protein with multifarious activities. Infect Genet Evol 2008,8(4),397-405
McBride R.; van Zyl M.; Fielding B.C.; The coronavirus nucleocapsid is a multifunctional protein. Viruses 2014,6(8),2991-3018
Li F; Li W; Farzan M; Harrison SC; Structural biology: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science (80-) 2005,309(5742),1864-8
Lu H.; Stratton C.W.; Tang Y.W.; Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020,92(4),401-402
Hoffmann M.; Kleine-Weber H.; Schroeder S.; SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020,181(2),271-280.e8
Tai W.; He L.; Zhang X.; Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 2020,17(6),613-620
Woo P.C.Y.; Huang Y.; Lau S.K.P.; Yuen K.Y.; Coronavirus genomics and bioinformatics analysis. Viruses 2010,2(8),1804-1820
Wu F.; Zhao S.; Yu B.; A new coronavirus associated with human respiratory disease in China. Nature 2020,579(7798),265-269
Venkataraman S.; Prasad B.V.L.S.; Selvarajan R.; RNA dependent RNA polymerases: Insights from structure, function and evolution. Viruses 2018,10,76-84
Morgenstern B.; Michaelis M.; Baer P.C.; Doerr H.W.; Cinatl J.; Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 2005,326(4),905-908
Agostini M.L.; Andres E.L.; Sims A.C.; Graham R.L.; Sheahan T.P.; Lu X.; Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018,9(2),e00221-e18
Lim S.Y.; Osuna C.; Lakritz J.; Chen E.; Yoon G.; Taylor R.; Galidesivir, a direct-acting antiviral drug, abrogates viremia in rhesus macaques challenged with zika virus. Open Forum Infect Dis 2017,4(Suppl. 1),S55-S55
Furuta Y.; Gowen B.B.; Takahashi K.; Shiraki K.; Smee D.F.; Barnard D.L.; Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013,100(2),446-454
Chan J.F.W.; Yip C.C.Y.; To K.K.W.; Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vivo and with clinical specimens. J Clin Microbiol 2020,58(5),e00310-e00320
Zhang W.; Du R.H.; Li B.; Molecular and serological investigation of 2019-nCoV infected patients: Implication of multiple shedding routes. Emerg Microbes Infect 2020,9(1),386-389
Yang Y.; Yang M.; Shen C.; Wang F.; Yuan J.; Li J.; Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections medRxiv. Cold Spring Harbor Laboratory Press 2019
Pang J.; Wang M.X.; Ang I.Y.H.; Tan S.H.X.; Lewis R.F.; Chen J.I-P.; Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): A systematic review. J Clin Med 2019,9(3),623
Arevalo-Rodriguez I.; Buitrago-Garcia D.; Simancas-Racines D.; Zambrano-Achig P.; Campo R. del; Ciapponi A.; False-negative results of initial RT-PCR assays for COVID-19: A systematic review. medRxiv 2020
Wikramaratna P.; Paton R.S.; Ghafari M.; Lourenco J.; Estimating false-negative detection rate of SARS-CoV-2 by RT-PCR. medRxiv 2020
Sinnott-Armstrong N.; Klein D.; Hickey B.; Evaluation of group testing for SARS-COV-2 RNA. medRxiv 2020,30
Shani-Narkiss H.; Gilday O.D.; Yayon N.; Landau I.D.; Efficient and practical sample pooling high-throughput pcr diagnosis of COVID-19. medRxiv 2020
Yelin I.; Aharony N.; Tamar E.S.; Argoetti A.; Messer E.; Berenbaum D.; Evaluation of COVID-19 RT-QPCR test in multi sample pools. Clin Infect Dis 2020,ciaa531
Wang W.; Xu Y.; Gao R.; Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020,323(18),1843-1844
Seah J.N.; Yu L.; Kwang J.; Localization of linear B-cell epitopes on infectious bronchitis virus nucleocapsid protein. Vet Microbiol 2000,75(1),11-16
Denac H.; Moser C.; Tratschin J.D.; Hofmann M.A.; An indirect ELISA for the detection of antibodies against porcine reproductive and respiratory syndrome virus using recombinant nucleocapsid protein as antigen. J Virol Methods 1997,65(2),169-181
Wang N.; Li S.Y.; Yang X.L.; Serological evidence of bat SARS-related coronavirus infection in humans, China. Virol Sin 2018,33(1),104-107
Woo P.C.Y.; Lau S.K.P.; Wong B.H.L.; Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia. J Clin Microbiol 2004,42(5),2306-2309
Berry J.D.; Hay K.; Rini J.M.; Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs 2010,2(1),53-66
Amanat F.; Stadlbauer D.; Strohmeier S.; A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med 2020,26(7),1033-1036
Long Q.X.; Tang X.J.; Shi Q.L.; Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020,26(8),1200-1204
Gootenberg J.S.; Abudayyeh O.O.; Lee J.W.; Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 2017,356(6336),438-442
Chen J.S.; Ma E.; Harrington L.B.; CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science 2018,360(6387),436-439
Li S.Y.; Cheng Q.X.; Wang J.M.; CRISPR-Cas12a-assisted nucleic acid detection. Cell Discov 2018,4,20
Jolany Vangah S.; Katalani C.; Booneh H.A.; Hajizade A.; Sijercic A.; Ahmadian G.; CRISPR- based diagnosis of infectious and noninfectious diseases. Biol Proced Online 2020,14,22
Myhrvold C.; Freije C.A.; Gootenberg J.S.; Abudayyeh O.O.; Field-deployable viral diagnostics using CRISPR-Cas13. Science 2018,360(6387),444-448
Ai J.W.; Zhou X.; Xu T.; CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis. Emerg Microbes Infect 2019,8(1),1361-1369
Lucia C.; Federico P.; Alejandra G.C.; An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12. bioRxiv 2020
Broughton J.P.; Deng X.; Yu G.; CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol 2020,38(7),870-874
Suganya S.; Divya S.; Parani M.; Severe acute respiratory syndrome‐coronavirus‐2: Current advances in therapeutic targets and drug development. Rev Med Virol 2020,1-9
Giovane R.A.; Rezai S.; Cleland E.; Henderson C.E.; Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Rev Med Virol 2020,30(5),e2136
Valle C.; Martin B.; Touret F.; Drugs against SARS-CoV-2: What do we know about their mode of action? Rev Med Virol 2020,30(6),1-10
Shahverdi M.; Darvish M.; Therapeutic measures for the novel coronavirus: A review of current status and future perspective. Curr Mol Med 2021,21(7),562-572
McCreary E.K.; Pogue J.M.; Coronavirus disease 2019 treatment: A review of early and emerging options Open forum infectious diseases 2020,7
Aljofan M.; Gaipov A.; Covid-19 treatment: The race against time 2020,em227
Martin RE; Marchetti RV; Cowan AI; Howitt SM; Bröer S; Kirk K; Chloroquine transport via the malaria parasite’s chloroquine resistance transporter. Science (80-) 2009,325(5984),1680-2
Savarino A.; Boelaert J.R.; Cassone A.; Majori G.; Cauda R.; Effects of chloroquine on viral infections: An old drug against today’s diseases? Lancet Infect Dis 2003,3(11),722-727
Keyaerts E.; Vijgen L.; Maes P.; Neyts J.; Van Ranst M.; In vivo inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004,323(1),264-268
Vincent M.J.; Bergeron E.; Benjannet S.; Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005,2,69
Kono M.; Tatsumi K.; Imai A.M.; Saito K.; Kuriyama T.; Shirasawa H.; Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK. Antiviral Res 2008,77(2),150-152
Madrid P.B.; Chopra S.; Manger I.D.; A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One 2013,8(4),e60579
Liu X.; Wang X.J.; Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics 2020,47(2),119-121
Takla M.; Jeevaratnam K.; Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. Saudi Pharm J 2020,28(12),1760-1776
Chan J.F.W.; Chan K.H.; Kao R.Y.T.; Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013,67(6),606-616
Saftig P.; Klumperman J.; Lysosome biogenesis and lysosomal membrane proteins: Trafficking meets function. Nat Rev Mol Cell Biol 2009,10(9),623-635
Kaufmann A.M.; Krise J.P.; Lysosomal sequestration of amine-containing drugs: Analysis and therapeutic implications. J Pharm Sci 2007,96(4),729-746
An J.; Woodward J.J.; Sasaki T.; Minie M.; Elkon K.B.; Cutting edge: Antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction. J Immunol 2015,194(9),4089-4093
Zhou D.; Dai S.M.; Tong Q.; COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020,75(7),1667-1670
Al-Bari M.A.A.; Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect 2017,5(1),e00293
Kužnik A.; Benčina M, Švajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011,186(8),4794-4804
van den Borne B.E.E.M.; Dijkmans B.A.C.; de Rooij H.H.; le Cessie S.; Verweij C.L.; Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-α interleukin 6, and interferon-γ production by peripheral blood mononuclear cells. J Rheumatol 1997,24(1),55-60
Devaux C.A.; Rolain J-M.; Colson P.; Raoult D.; New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19? Int J Antimicrob Agents 2020,55(5),105938
Gao J.; Tian Z.; Yang X.; Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020,14(1),72-73
Bright R.; Letter of authorization - chloroquine phosphate and hydroxychloroquine sulfate Available from: 2020
Borba M.G.S.; Val F.F.A.; Sampaio V.S.; Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection: A randomized clinical trial. JAMA Netw Open 2020,3(4),e208857
Boretti A.; Banik B.; Castelletto S.; Mechanism of action of chloroquine/hydroxychloroquine for COVID-19 infection. Coronaviruses 2020,1,1
Horby P.; Mafham M.; Linsell L.; Effect of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 2020,383(21),2030-2040
Lammers A.J.J.; Brohet R.M.; Theunissen R.E.P.; Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. Int J Infect Dis 2020,101,283-289
Kashour Z.; Riaz M.; Garbati M.A.; Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis. J Antimicrob Chemother 2021,76(1),30-42
Disbrow GL; Letter revoking EUA for chloroquine phosphate and hydroxychloroquine sulfate 2020
Castelnuovo A.D.; Costanzo S.; Antinori A.; Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. Eur J Intern Med 2020,82,38-47
Catteau L.; Dauby N.; Montourcy M.; Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: A nationwide observational study of 8075 participants. Int J Antimicrob Agents 2020,56(4),106144
Gasmi A.; Peana M.; Noor S.; Chloroquine and hydroxychloroquine in the treatment of COVID-19: The never-ending story. Appl Microbiol Biotechnol 2021,105(4),1333-1343
Carafoli E.; Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection. Biochem Biophys Res Commun 2021,538,156-162
González Canga A.; Sahagún Prieto A.M.; Diez Liébana M.J.; Fernández Martínez N.; Sierra Vega M.; García Vieitez J.J.; The pharmacokinetics and interactions of ivermectin in humans-a mini-review. AAPS J 2008,10(1),42-46
Wagstaff K.M.; Sivakumaran H.; Heaton S.M.; Harrich D.; Jans D.A.; Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J 2012,443(3),851-856
Tay M.Y.F.; Fraser J.E.; Chan W.K.K.; Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res 2013,99(3),301-306
Lundberg L.; Pinkham C.; Baer A.; Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Res 2013,100(3),662-672
Götz V.; Magar L.; Dornfeld D.; Giese S.; Pohlmann A.; Höper D.; Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci Rep 2016,18(6),23138
Yang S.N.Y.; Atkinson S.C.; Wang C.; The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res 2020,177,104760
Caly L.; Druce J.D.; Catton M.G.; Jans D.A.; Wagstaff K.M.; The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vivo. Antiviral Res 2020,178,104787
Ahmed S.; Karim M.M.; Ross A.G.; A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis 2021,103,214-216
Chaccour C.; Casellas A.; Blanco-Di Matteo A.; The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021,32,100720
Warren T.K.; Jordan R.; Lo M.K.; Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016,531(7594),381-385
Sheahan T.P.; Sims A.C.; Leist S.R.; Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020,11(1),222
de Wit E.; Feldmann F.; Cronin J.; Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA 2020,117(12),6771-6776
Wang Y.; Zhang D.; Du G.; Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020,395(10236),1569-1578
Beigel J.H.; Tomashek K.M.; Dodd L.E.; Mehta A.K.; Zingman B.S.; Kalil A.C.; Remdesivir for the treatment of COVID-19 — preliminary report. N Engl J Med 2020,383,1813-1826
Nili A.; Farbod A.; Neishabouri A.; Mozafarihashjin M.; Tavakolpour S.; Mahmoudi H.; Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. Rev Med Virol 2020,30(6),1-13
Glowacka I.; Bertram S.; Müller M.A.; Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 2011,85(9),4122-4134
Simmons G.; Gosalia D.N.; Rennekamp A.J.; Reeves J.D.; Diamond S.L.; Bates P.; Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 2005,102(33),11876-11881
Matsuyama S.; Nagata N.; Shirato K.; Kawase M.; Takeda M.; Taguchi F.; Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol 2010,84(24),12658-12664
Shulla A.; Heald-Sargent T.; Subramanya G.; Zhao J.; Perlman S.; Gallagher T.; A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol 2011,85(2),873-882
Kawase M.; Shirato K.; van der Hoek L.; Taguchi F.; Matsuyama S.; Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol 2012,86(12),6537-6545
Iwata-Yoshikawa N.; Okamura T.; Shimizu Y.; Hasegawa H.; Takeda M.; Nagata N.; TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol 2019,93(6),e01815-e01818
Shirato K.; Kawase M.; Matsuyama S.; Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology 2018,517,9-15
Hoffmann M.; Schroeder S.; Kleine-Weber H.; Müller M.A.; Drosten C.; Pöhlmann S.; Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19. Antimicrob Agents Chemother 2020,64(6),e00754-e20
Doi K.; Ikeda M.; Hayase N.; Moriya K.; Morimura N.; Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with COVID-19: A case series. Crit Care 2020,24(1),392
Chandwani A.; Shuter J.; Lopinavir/ritonavir in the treatment of HIV-1 infection: A review. Ther Clin Risk Manag 2008,4,1023-1033
Chu C.M.; Cheng V.C.C.; Hung I.F.N.; Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 2004,59(3),252-256
de Wilde A.H.; Jochmans D.; Posthuma C.C.; Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother Available from: 2014,58(8),4875-4884
Zumla A.; Chan J.F.W.; Azhar E.I.; Hui D.S.C.; Yuen K.Y.; Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016,15(5),327-347
Tahir Ul Qamar M.; Alqahtani S.M.; Alamri M.A.; Chen L.L.; Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal 2020,10(4),313-319
Cao B.; Wang Y.; Wen D.; A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med Available from: 2020,382(19),1787-1799
Sanders J.M.; Monogue M.L.; Jodlowski T.Z.; Cutrell J.B.; Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA Available from: 2020,323(18),1824-1836
Yao T.T.; Qian J.D.; Zhu W.Y.; Wang Y.; Wang G.Q.; A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol 2020,92(6),556-563
Rocha-Pereira J.; Jochmans D.; Dallmeier K.; Leyssen P.; Nascimento M.S.J.; Neyts J.; Favipiravir (T-705) inhibits in vivo norovirus replication. Biochem Biophys Res Commun 2012,424(4),777-780
Oestereich L.; Lüdtke A.; Wurr S.; Rieger T.; Muñoz-Fontela C.; Günther S.; Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014,105(1),17-21
Doi Y.; Hibino M.; Hase R.; A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother 2020,64(12),e01897-e20
Cai Q.; Yang M.; Liu D.; Experimental treatment with favipiravir for covid-19: An open-label control study. Engineering (Beijing) 2020,6(10),1192-1198
Blaising J.; Polyak S.J.; Pécheur E.I.; Arbidol as a broad-spectrum antiviral: An update. Antiviral Res 2014,107,84-94
Gagarinova V.M.; Ignat’eva G.S.; Sinitskaia L.V.; Ivanova A.M.; Rodina M.A.; Tur’eva A.V.; The new chemical preparation arbidol: Its prophylactic efficacy during influenza epidemics. Zh Mikrobiol Epidemiol Immunobiol 1993(5),40-43
Titova O.N.; Petrova M.A.; Shklyarevich N.A.; Kuzubova N.A.; Aleksandrov A.L.; Kovaleva L.F.; Efficacy of arbidol in the prevention of virus-induced exacerbations of bronchial asthma and chronic obstructive pulmonary disease. Ter Arkh 2018,90(8),48-52
Khamitov R.A.; Loginova S.Ia.; Shchukina V.N.; Borisevich S.V.; Maksimov V.A.; Shuster A.M.; Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol 2008,53(4),9-13
Vankadari N.; Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents 2020,56(2),105998
Wang M.; Cao R.; Zhang L.; Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vivo. Cell Res 2020,30(3),269-271
Yang C.; Ke C.; Yue D.; Li W.; Hu Z.; Liu W.; Effectiveness of arbidol for covid-19 prevention in health professionals. Front Public Health 2020,8,249
Chen C.; Zhang Y.; Huang J.; Yin P.; Cheng Z.; Wu J.; Favipiravir versus arbidol for COVID-19: A randomized clinical trial. medRxiv 2020
Xu P.; Huang J.; Fan Z.; Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: A retrospective multicenter cohort study. Microbes Infect 2020,22(4-5),200-205
Nojomi M.; Yassin Z.; Keyvani H.; Effect of arbidol (umifenovir) on covid-19: A randomized controlled trial. BMC Infect Dis 2020,20(1),954
Zhu Z.; Lu Z.; Xu T.; Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect 2020,81(1),e21-e23
Gao W.; Chen S.; Wang K.; Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: A retrospective case series. Virol J 2020,17(1),162
Mehta P.; McAuley D.F.; Brown M.; Sanchez E.; Tattersall R.S.; Manson J.J.; COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020,395(10229),1033-1034
Alattar R.; Ibrahim T.B.H.; Shaar S.H.; Abdalla S.; Shukri K.; Daghfal J.N.; Tocilizumab for the treatment of severe coronavirus disease 2019 J Med Virol 2020; jmv25964 Available from:
Coomes E.A.; Haghbayan H.; Interleukin-6 in COVID-19: A systematic review and meta-analysis. Rev Med Virol 2020,30(6),1-9
Toniati P.; Piva S.; Cattalini M.; Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020,19(7),102568
Klopfenstein T.; Zayet S.; Lohse A.; Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect 2020,50(5),397-400
Sciascia S.; Aprà F.; Baffa A.; Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 2020,38(3),529-532
Guaraldi G.; Meschiari M.; Cozzi-Lepri A.; Tocilizumab in patients with severe COVID-19: A retrospective cohort study. Lancet Rheumatol 2020,2(8),e474-e484
Villar J.; Ferrando C.; Martínez D.; Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir Med 2020,8(3),267-276
Horby P.; Lim W.S.; Emberson J.R.; Dexamethasone in hospitalized patients with COVID-19 — preliminary report. N Engl J Med 2021,384(8),693-704
Lammers T.; Sofias A.M.; van der Meel R.; Dexamethasone nanomedicines for COVID-19. Nat Nanotechnol 2020,15(8),622-624
Khan M.M.; Noor A.; Madni A.; Shafiq M.; Emergence of novel coronavirus and progress toward treatment and vaccine. Rev Med Virol 2020,30(4),e2116